393 related articles for article (PubMed ID: 29802087)
21. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier A; Baldini C; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2018 Sep; 101():160-164. PubMed ID: 30071444
[TBL] [Abstract][Full Text] [Related]
23. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.
Dömling A; Holak TA
Angew Chem Int Ed Engl; 2014 Feb; 53(9):2286-8. PubMed ID: 24474145
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 in disease.
Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
[TBL] [Abstract][Full Text] [Related]
25. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
26. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
28. Part II: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
[No Abstract] [Full Text] [Related]
29. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
30. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
31. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in head and neck cancer: evidence and perspectives.
Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
[TBL] [Abstract][Full Text] [Related]
33. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
36. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
37. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
38. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Teng F; Meng X; Kong L; Yu J
Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
[TBL] [Abstract][Full Text] [Related]
39. [The biological rationale for immunotherapy in cancer].
Benzaquen J; Marquette CH; Glaichenhaus N; Leroy S; Hofman P; Ilié M
Rev Mal Respir; 2018 Feb; 35(2):206-222. PubMed ID: 29428191
[TBL] [Abstract][Full Text] [Related]
40. Resistance Mechanisms to Anti-PD Cancer Immunotherapy.
Vesely MD; Zhang T; Chen L
Annu Rev Immunol; 2022 Apr; 40():45-74. PubMed ID: 35471840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]